To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

NOVELLO, Silvia;
2014-01-01

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
2014
25
1681
1690
Kerr KM;Bubendorf L;Edelman MJ;Marchetti A;Mok T;Novello S;O'Byrne K;Stahel R;Peters S;Felip E;Panel Members;Panel Members
File in questo prodotto:
File Dimensione Formato  
Second ESMO consensus conference on lung cancer_ pathology and molecular biomarkers for non-small-cell lung cancer _ Elsevier Enhanced Reader.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 6.5 MB
Formato Adobe PDF
6.5 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/151400
Citazioni
  • ???jsp.display-item.citation.pmc??? 91
  • Scopus 249
  • ???jsp.display-item.citation.isi??? 213
social impact